NTP-ATENOLOL/CHLORTHALIDONE TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ATENOLOL; CHLORTHALIDONE

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

C07CB03

SNN (starptautisko nepatentēto nosaukumu):

ATENOLOL AND OTHER DIURETICS

Deva:

50MG; 25MG

Zāļu forma:

TABLET

Kompozīcija:

ATENOLOL 50MG; CHLORTHALIDONE 25MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

30/100

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0216877002; AHFS:

Autorizācija statuss:

CANCELLED PRE MARKET

Autorizācija datums:

2015-08-06

Produkta apraksts

PRODUCT MONOGRAPH
Pr
NTP-ATENOLOL/CHLORTHALIDONE
(atenolol/chlorthalidone tablets, USP)
50/25 mg and 100/25 mg
Antihypertensive Agent
Teva Canada Limited
Date of Preparation:
30 Novopharm Court
July 12, 2013
Toronto, Ontario
Canada, M1B 2K9
Submission Control No: 165857
_Page _
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
....................................................................................................
9
DRUG INTERACTIONS
..................................................................................................
13
DOSAGE AND ADMINISTRATION
..............................................................................
15
OVERDOSAGE
.................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 17
STORAGE AND STABILITY
..........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
20
PHARMACEUTICAL INFORMATION
..........................................................................
20
PHARMACEUTICAL INFORMATION
..........................................................................
21
CLINICAL TRIALS
..................................................................................